Description: Fagron NV provides pharmaceutical compounding services to hospitals, pharmacies, clinics, and patients worldwide. The company operates through four segments: Fagron Europe, Fagron South America, Fagron North America, and HL Technology. It prepares personalized medication in its sterile and non-sterile facilities. The company also innovates concepts, products, and vehicles developed by Fagron. In addition, it offers conditioned, repackaged, and distributed pharmaceutical raw materials, supplies, and equipment that pharmacists need to prepare medication in the pharmacy. Further, the company develops and produces precision components and orthopedic tools for dental and medical industry professionals; and supplies compounding services, brands, and essentials to its customers. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Home Page: www.fagron.com
Venecoweg 20A
Nazareth,
9810
Belgium
Phone:
32 8 001 28 80
Officers
| Name | Title |
|---|---|
| Mr. Rafael Padilla | CEO & Executive Director |
| Ms. Karin de Jong | CFO & Executive Director |
| Ms. Vera Bakker | Chief Operating Officer |
| Karen Berg | Global Investor Relations Manager |
| Mr. Johan Verlinden | Head of Legal, Mergers & Acquisitions |
Exchange: OTCGREY
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 15.3846 |
|---|---|
| Trailing PE: | 17.8839 |
| Price-to-Book MRQ: | 2.9355 |
| Price-to-Sales TTM: | 1.7775 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3647 |